$Bob's and Jbem's Bitchin' Bios

[BioSpecialist]

IGXT (MC $48 M) Great time to load up guys after they resubmit the NDA early this Week .


Market Cap : US$48 Million / Cash US$8.2 million /very low burn-rate of ~$700K a Quarter =Cash untill 2020+ EXCLUDING payments from new partnerships ,profitability expected quickly with approval for Rizaport and Tadalafil both approval expected in 2018, if everything goes well then this stock could run to $10 even then it wouldnt be expensive = ONE OF MOST ATTRACTIVE AND UNDERPRICED PHARMA STOCK YOU CAN GET AT THIS TIME .I LOVE IT


Intelgenx (IGXT)

Markt-Cap $48 Million
Cash 8.1 Million
Price: $0.73


FDA Decision for Rizaport(Migraine) in Q2/2018 (Peak Sales $60-80 Million)


NDA submission for Tadalafil (erectile dysfunction) this Quarter >> FDA approval in 2H 2018 (Peak Sales $150++ Million)


Start Phase 2a for Montulukast (Alzheimer disease) this Quarter >> Phase 2a Results in 1H/2018 (Potential BLOCKBUSTER Drug)


Opioid dependence drug partnered with Par Pharma >> FDA approval depends on patent ruling (Peak Sales $100++ Million) 30-Month Stay already expired



MEGA Pipeline
http://s2.q4cdn.com/790425727/files/images/2017/IntelGenx-Product-Portfolio-and-Pipeline-July-2017.jpg


Presentation
http://s2.q4cdn.com/790425727/files/doc_presentations/2017/09/INTELGENX-Presentation-September-2017_final.pdf


https://investorintel.com/sectors/biotech/biotech-intel/intelgenx-thin-film-market/